Merck Reports Phase 2 Results for Vibostolimab Plus Keytruda in Advanced Melanoma

Merck today announced Phase 2 results from the KEYVIBE-001 trial evaluating MK-7684A, a coformulation of vibostolimab (anti-TIGIT) and pembrolizumab (Keytruda), in patients with advanced melanoma. The trial demonstrated an objective response rate of 43% in PD-L1-positive patients who had not received prior anti-PD-1 therapy.